ArticleSleep & breathing = Schlaf & Atmung2026
The mechanism of S100A4 regulating Fibulin-5 expression to promote the proliferation and migration of PASMCs.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposePulmonary hypertension is a serious pulmonary vascular disease. During the course of development, pulmonary artery smooth muscle cells (PASMCs) exhibit hyperplasia, enhanced anti-apoptotic effect, cell deformation, and migration. S100A4 protein is a member of the S100 protein family, which can deform and migrate arterial smooth muscle cells. Pulmonary hypertension can increase S100A4 protein expression. However, the underlying mechanism by which S100A4 is involved in the progression of pulmonary hypertension remains unclear.
methodsIn this study, the effects of recombinant human S100A4 protein treatment on cell proliferation, migration, and Fibulin-5 expression, as well as the effects of Fibulin-5 interference on cell proliferation and migration, were evaluated in human PASMCs. Subsequently, the impact of Fibulin-5 interference on cell proliferation and migration following recombinant human S100A4 protein treatment was investigated.
resultsIt was demonstrated that exogenous S100A4 upregulated Fibulin-5 expression, thereby promoted PASMC proliferation. Conversely, Fibulin-5 interference was found to reverse the effects of Re-S100A4.
conclusionThis study further complements and improves the mechanism network related to pulmonary hypertension, thereby demonstrating that S100A4 and Fibulin-5 may become a new target for clinical intervention in pulmonary hypertension.
Indexed as
Identifiers
41922812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.